Cryptococcosis, mainly caused by Cryptococcus neoformans/gattii species complexes, is a lethal infection in both immunosuppressive and immunocompetent populations. With the upgrade of detection methods and the increase of clinical knowledge, the incidence rate of cryptococcosis is increasing, and it has become one of the most important fungi threatening human health. In recent years, great progress has been made in this field, including the taxonomy and nomenclature of Cryptococcus spp., laboratory diagnostic methods and antifungal susceptibility tests, as well as the characteristics and treatments of cryptococcosis. This article reviews the above contents, in order to improve the clinical and laboratory understanding of the Cryptococcus spp., and realize the timely diagnosis and early treatment of cryptococcosis.
In recent years, due to the extensive usage of immunosuppressant and the rise of patients with cancers and organ transplantation, the incidence rate of invasive fungal infection, especially invasive pulmonary fungal infection, has increased. Besides the clinical manifestations, medical history and imaging, the diagnosis of pulmonary mycosis mainly depends on pathogen detection methods in clinical microbiology laboratory. However, due to the difficulty in fungi culturing and the low sensitivity of smear microscopy, better molecular biology methods are needed. To date, the emergence of metagenomic next-generation sequencing (mNGS) has improved the identification rate of pulmonary fungal infections. mNGS is significantly superior to traditional detection methods in rapid, accurate, and comprehensive determination of fungi from various clinical specimens, especially atypical fungi. However, some problems in mNGS method have to be addressed including sample collection, report interpretation, and its combination with traditional microbiology methods. With the in-depth discussion and solution of the above problems, mNGS will be indispensable to the etiological diagnosis of pulmonary invasive fungal infection.
Compared to classical Klebsiella pneumoniae, hypervirulent Klebsiella pneumoniae (hvKP) exhibits stronger pathogenicity and a greater ability to evade host immune responses. Infections caused by hvKP typically manifest as more severe diseases with higher mortality rates, thereby increasing the complexity and challenges of clinical treatment. The emergence of carbapenem-resistant hvKP (CR-hvKP) exacerbates this predicament. Although there is still confusion regarding the clinical definition and detection standards for hvKP, this article systematically explains the clinical infection characteristics, identification methods, and mechanisms behind the emergence of CR-hvKP. This can enhance clinical staff’s vigilance towards hvKP infections and offer comprehensive and detailed considerations for the diagnosis and treatment of such strains.